Funded project
IP-NFT
ARTAN Bio - Mutation-Specific Codon Suppression for Aging and Longevity

ARTAN Bio - Mutation-Specific Codon Suppression for Aging and Longevity

Age-related diseases
Cancer
Nonsense Suppression
ARTAN is a biotechnology company developing first-in-class interventions to tackle the most frequent nonsense mutations implicated in a wide range of age-related diseases and cancers. These nonsense mutations induce premature stops of protein translation when occurring in coding regions.
Funding
$ 91,300
Initiated
2.8.2023
Approval
60% Voted Yes
Anthony Schwartz, Ph.D
Project Manager
Michael Torres, Ph.D.
Principal Investigator
AT A GLANCE

Stage
Early stage preclinical discovery

Area
Drug development


Status

Ongoing


Patent Status

Not filed yet

PROJECT LINKS

Background

Nonsense mutations, alterations in the DNA or RNA sequence that produce a premature termination codon (PTC), result in the production of incomplete, nonfunctional proteins. These mutations have profound implications, being associated with roughly 10% of genetic diseases, such as cystic fibrosis.The accumulation of nonsense mutations have been implicated in age-related diseases like cancer and Alzheimer's. Particularly common is the mutation that changes a CGA codon into an opal-stop codon.. To combat the negative effects of these mutations, several strategies have been employed. These include the inhibition of Nonsense-Mediated mRNA Decay (NMD) using drugs and the process of pseudouridylation. While these methods have shown some success, they are not without drawbacks, including potential low efficiency and the risk of creating aberrant proteins.

Aims, Hypothesis & Results

Aim:

To engineer and validate a nonsense  suppression system that can effectively and specifically target nonsense codons without competing with normal tRNA, aiming to restore proper protein translation in genes affected by these mutations.

Hypothesis:

An bio-inspired nonsense suppression system can recognize the premature stop codon introduced by nonsense mutations n and replace it with its correct amino acid. This action would restore normal protein translation without significantly impacting natural termination codons or generating aberrant proteins.

Result (Preliminary):

Initial ribosome profiling data from experiments using a cancer cell line, which has anonsense mutation in a tumor suppressor gene, indicates that the nonsense suppression system  can effectively restore protein levels. The nonsense suppression system demonstrated better specificity compared to existing interventions like G418, as it did not show significant read-through at natural termination codons. Furthermore, AAV was identified as a promising vector for delivering the nonsense suppression system, given its efficiency in transducing various tissues and its previous clinical successes.

Timeline

Milestone 1 – Start of the project - project kickoff meeting after on-chain approval of the proposal.

Phase 1 : Design & generate a nonsense suppression construct for use in an AAV vector. 

Milestone 2 – Go / no go check – Completion of phase 1 and presentation of results in a dedicated meeting or at a quarterly review.

Phase 2 : In vitro testing of selected vectors/oligos. 

Milestone 3 – End of the project - Completion of phase 2 and presentation of results in a dedicated meeting or at a quarterly review, proposal for next round of funding. Note, a provisional patent could be filed at this stage.

Required Funding: $ 91,300

Status: Ongoing

Duration: 6 Months

VitaDAO Board Evaluation Writeup

The emerging nonsense suppression therapeutic strategy offers a promising approach to suppress nonsense mutations.. Led by a seasoned drug developer, preliminary results show potential in rescuing vital tumor-suppressor genes, providing a versatile "pipeline in a pill" solution due to its shared mechanism across diseases. Its compact payload size further streamlines delivery, addressing a nuanced aspect of aging. However, the approach treads on uncharted grounds, presenting challenges like potential toxicity, delivery issues, and uncertainties in biology that might yield off-target effects.

Projects supported

Non Consectetur Necessitatibus

Aspernatur corrupti ea cupiditate possimus ullam nesciunt et. Dignissimos nobis minima assumenda qui provident possimus et ipsa. Eum sapiente sit numquam nemo consequa

$293,00
raised
View Project

Eum Harum Asperiores Id

Molestias et qui commodi. Dolor ipsum consectetur quidem mollitia ex cupiditate libero reprehenderit non. Repudiandae facere consequatur adipisci ipsum ipsa. Quia recusandae cupiditate ipsum laborum consequuntur quos. Cupiditate veniam est et sunt dolor praesentium sed voluptas distin

$293,00
raised
View Project

Ex Temporibus Perferendis

Sit libero dolorem voluptate voluptatem. Pariatur sapiente dolor aut est explicabo tenetur est. A id ipsa officiis recusandae. Nemo est voluptatem non delectus eum alias. Ut maiores aliquam illum. Velit recusandae aut. Cupiditate unde non tempore. Facilis vero repudianda

$293,00
raised
View Project

Dolorum Quia

Labore voluptates nostrum qui repudiandae. Dolorem qui ullam quod labore iusto eum aut et consequatur. Illum enim quia sit. Itaque ut corrupti ducimus cumque quos qui quis. A amet perspiciatis assumenda corrupti qui facilis dolorem. Et quisquam soluta non necessitatibus cumque ex

$293,00
raised
View Project

Earum Est Dolorem

Aut asperiores labore illo aut reiciendis neque. Delectus officiis veritatis non enim blanditiis occaecati. Rerum cupiditate officiis explicabo. Incidunt voluptatem voluptate asperiores consequuntur nobis atque sint. Quibusdam odio expedita dolores aut quia voluptas molestiae libero. Necessitatibus

$293,00
raised
View Project

Culpa Possimus

Quasi est ut id amet at ad nesciunt amet corrupti. Commodi sint et ducimus dolorum nisi enim necessitatibus iste soluta. Qui sit rerum dolores temporibus molestiae fuga sapiente. Incidunt quaerat unde quaerat rerum et debitis praesentium et ipsum. Aut magni cupiditate odit eligendi. Illo quod

$293,00
raised
View Project

Aperiam Et Quis Et

Praesentium esse velit assumenda incidunt maxime et. Sit iure odit rerum repellat maxime. Dignissimos deleniti architecto ab at amet animi architecto. Sequi dicta sed est nobis consequatur aspernatur aliquam et. Distinctio sit soluta. Optio et ullam placeat ut aut in maiores. Nemo et s

$293,00
raised
View Project

Voluptas Quam Sapiente

Excepturi ut quisquam rerum dolor et iste et rerum quo. Et atque ut animi excepturi excepturi ut sint. Minima dolor saepe omnis eligendi. Ab ea ut et accusamus in harum. Rerum possimus sit tempora. At est iste fuga ducimus beatae deleniti ipsum. Eligendi quis exercitationem ut. Omnis u

$293,00
raised
View Project

Aut Accusantium Ut

Aut a laborum soluta et magni. Adipisci in aut et possimus enim. Et omnis id tempora at ea dolorum eaque. Et iste similique eum suscipit aspernatur. Voluptate aliquid omnis et optio recusandae qui voluptate. Voluptas eum illo excepturi. Sed quo dolorem repudiandae molestiae at eligendi necessita

$293,00
raised
View Project

Nisi

Voluptatem aut ut blanditiis et at quis id. Excepturi iure quia molestias deserunt. Repellat veniam qui voluptates molestias non. Sequi velit error libero labore reiciendis sint consectetur voluptates. Vel vero sit recusandae animi. Quasi id molestiae nam doloremque saepe dolorum ut. Error ut aut l

$293,00
raised
View Project
Latest Project Updates
No items found.
2
August
2023
Project Initiated!

Discover more projects & initiatives

Humanity

Equity

Humanity is a quantified-self app that connects wearables and activity apps to monitor digital biomarkers. The app generates a proprietary aging score, helping users understand activities that slow down or reverse their aging rate. The company uses behavior modification tools and develops biomarkers to guide users toward better healthspan interventions.

$ 50,000
raised
View Project

Matrix Bio

IP-NFT

VitaDAO and the Gorbunova Lab are launching Matrix Bio, a cutting-edge research venture leveraging the anti-cancer and pro-longevity effects of high molecular weight hyaluronic acid from naked mole rat to human.

$ 300,000
raised
View Project

BE Therapeutics - Brain Tissue Replacement

Equity

The neocortex, the part that underlies our highest cognitive functions and self-identity, can be replaced by progressively replacing tissue areas over time without significant disruption in function or self-identity. This offers the possibility of age reversal for the neocortex through progressive tissue replacement.

$ 100,000
raised
View Project

ExcepGen Inc - RNA therapeutics for longevity

Equity

ExcepGen uses its RNAx platform to develop advanced vaccines that address viral infections linked to premature aging and shortened lifespan. The platform improves RNA cargo's effectiveness, promoting significant protein production for enhanced protection.

$ 100,000
raised
View Project

Are you working on the next longevity science breakthrough?

Apply for funding

About VitaDAO

Who can apply?
What types of projects do you fund?
What is the application structure?
Who owns IP from funded projects?
What project stages do you fund?